Actively Recruiting
Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients
Led by J.M. de Laat · Updated on 2024-12-18
20
Participants Needed
1
Research Sites
239 weeks
Total Duration
On this page
Sponsors
J
J.M. de Laat
Lead Sponsor
R
Radboud University Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
Patients with the Multiple Endocrine Neoplasia type 1 (MEN1) syndrome are genetically predisposed for developping multiple pancreatic neuro-endocrine tumours (pNET). The management of small (pNET) in both MEN1 and sporadic cases, pose a major clinical challenge. At present, pancreatic surgery is the only curative treatment but it is associated with high morbidity. To reduce the morbidity ascosiated with surgery and thereby potentially improve quality of life for MEN1 patients introduction of less invasive techniques for treatment of pNET is important. High-dose-high precision MR-guided radiotherapy (MRgRT) holds promise as a new less invasive treatment option for pNET. The aim of this study is to assess efficiacy and safety of MRgRT for treatment of pNET in MEN1 patients.
CONDITIONS
Official Title
Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with pNET lesions measuring between 2 cm and 3 cm
- Patients with pNET lesions between 1.0 and 2.0 cm showing moderate growth (2-4 mm/year) on follow-up scans
- Patients with pNET lesions between 1.0 and 2.0 cm showing minimal growth (1 mm/year) confirmed on 3 or more sequential scans
- Patients with remaining 1.0 to 2.0 cm lesions after previous removal of a larger lesion
- Patients with an indication for surgery
You will not qualify if you...
- pNET lesions larger than 3 cm
- Rapidly growing pNET lesions with growth over 4 mm per year
- Symptomatic pNET due to hormone production, except gastrinomas in the duodenum submucosa
- Receiving somatostatin analog treatment
- Receiving chemotherapy
- Received peptide receptor radionuclide therapy in the past 12 months
- History of radiotherapy in the upper abdomen
- Contraindications for MRI such as claustrophobia or incompatible implants
- Pregnancy
- Presence of metastatic disease
- WHO performance status 3 or 4
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UMC Utrecht
Utrecht, Netherlands, 3584 CX
Actively Recruiting
Research Team
J
Joanne M de Laat, Md, PhD
CONTACT
G
Gerlof D Valk, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here